1. Home
  2. ENTA vs JYNT Comparison

ENTA vs JYNT Comparison

Compare ENTA & JYNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENTA
  • JYNT
  • Stock Information
  • Founded
  • ENTA 1995
  • JYNT 2010
  • Country
  • ENTA United States
  • JYNT United States
  • Employees
  • ENTA N/A
  • JYNT N/A
  • Industry
  • ENTA Biotechnology: Pharmaceutical Preparations
  • JYNT Multi-Sector Companies
  • Sector
  • ENTA Health Care
  • JYNT Miscellaneous
  • Exchange
  • ENTA Nasdaq
  • JYNT Nasdaq
  • Market Cap
  • ENTA 164.6M
  • JYNT 149.5M
  • IPO Year
  • ENTA 2013
  • JYNT 2014
  • Fundamental
  • Price
  • ENTA $10.96
  • JYNT $7.89
  • Analyst Decision
  • ENTA Strong Buy
  • JYNT Strong Buy
  • Analyst Count
  • ENTA 5
  • JYNT 3
  • Target Price
  • ENTA $21.00
  • JYNT $16.33
  • AVG Volume (30 Days)
  • ENTA 518.3K
  • JYNT 93.7K
  • Earning Date
  • ENTA 11-17-2025
  • JYNT 11-06-2025
  • Dividend Yield
  • ENTA N/A
  • JYNT N/A
  • EPS Growth
  • ENTA N/A
  • JYNT N/A
  • EPS
  • ENTA N/A
  • JYNT N/A
  • Revenue
  • ENTA $64,806,000.00
  • JYNT $53,449,713.00
  • Revenue This Year
  • ENTA $0.07
  • JYNT $7.70
  • Revenue Next Year
  • ENTA N/A
  • JYNT $10.24
  • P/E Ratio
  • ENTA N/A
  • JYNT N/A
  • Revenue Growth
  • ENTA N/A
  • JYNT 277.36
  • 52 Week Low
  • ENTA $4.09
  • JYNT $7.74
  • 52 Week High
  • ENTA $15.34
  • JYNT $13.47
  • Technical
  • Relative Strength Index (RSI)
  • ENTA 54.87
  • JYNT 29.31
  • Support Level
  • ENTA $10.30
  • JYNT $8.24
  • Resistance Level
  • ENTA $11.45
  • JYNT $8.76
  • Average True Range (ATR)
  • ENTA 0.62
  • JYNT 0.28
  • MACD
  • ENTA -0.12
  • JYNT 0.01
  • Stochastic Oscillator
  • ENTA 41.67
  • JYNT 14.77

About ENTA Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

About JYNT The Joint Corp.

The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The Company has one operating business segment; The Franchise Operations segment which is comprised of the operating activities of the franchise business unit. The Franchise Operations segment derives revenue from customers by providing access to the Company's franchise license, which represents symbolic intellectual property.

Share on Social Networks: